Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2017 / Article

Research Article | Open Access

Volume 2017 |Article ID 4240136 | 14 pages | https://doi.org/10.1155/2017/4240136

Comparative Analysis of AGE and RAGE Levels in Human Somatic and Embryonic Stem Cells under H2O2-Induced Noncytotoxic Oxidative Stress Conditions

Academic Editor: Gabriele Saretzki
Received03 Feb 2017
Revised27 Mar 2017
Accepted03 May 2017
Published17 Sep 2017


The accumulation of advanced glycation end products (AGEs) occurs in ageing and in many degenerative diseases as a final outcome of persistent oxidative stress on cells and organs. Environmental alterations taking place during early embryonic development can also lead to oxidative damage, reactive oxygen species (ROS) production, and AGE accumulation. Whether similar mechanisms act on somatic and embryonic stem cells (ESC) exposed to oxidative stress is not known; and therefore, the modelling of oxidative stress in vitro on human ESC has been the focus of this study. We compared changes in Nε-carboxymethyl-lysine (CML) advanced glycation end products and RAGE levels in hESC versus differentiated somatic cells exposed to H2O2 within the noncytotoxic range. Our data revealed that hESC accumulates CML and RAGE under oxidative stress conditions in different ways than somatic cells, being the accumulation of CML statistically significant only in somatic cells and, conversely, the RAGE increase exclusively appreciated in hESC. Then, following cardiac and neural differentiation, we observed a progressive removal of AGEs and at the same time an elevated activity of the 20S proteasome. We conclude that human ESCs constitute a unique model to study the consequence of an oxidative environment in the pluripotent cells of the embryo during the human preimplantation period.

1. Introduction

Aging is described as a progressive decline in the efficiency of physiological functions associated to increased susceptibility to disease and cell death [1] with the influence of genetic and environmental factors [2]. A number of studies have attempted to characterize the pathophysiology of aging and to find possibilities to counteract age-related diseases [3]. Currently, one of the most plausible and accepted mechanistic explanations of aging is the “free radical theory.” This theory states that aging and its related diseases are the consequence of reactive oxygen species- (ROS-) induced damage and of the inability to counteract these changes by endogenous antioxidant defences [4]. This unbalanced redox status is known as oxidative stress.

In general, ROS are more reactive oxygen species compared to free oxygen [5] and their effects inside the cell are determined by the subcellular source, duration, and location of these molecules [6]. In order to induce oxidative stress in a cell culture in vitro model, one of the prooxidant agents and ROS widely used is hydrogen peroxide (H2O2), which at physiological concentrations is involved in signalling mechanisms and cell metabolism. H2O2 reacts relatively slowly; however, it can also produce other ROS, which easily penetrate the cell membranes, directly damaging lipids, nucleic acids, and other macromolecules [7, 8]. H2O2 intracellular concentration is tightly controlled by various enzymatic and nonenzymatic antioxidant systems, and it is assumed to vary between 1 and 700 nM [9] depending on the cellular type and the specific system; so intracellular steady-state concentrations of H2O2 above 1 μM are considered the origin of oxidative stress, inducing growth arrest and cell death [10].

Human embryonic stem cells (hESCs) have attracted huge attention for their potential applications in cell therapy, but much still remains to be explained about how their unique properties are altered by oxidative stress [11]. In preliminary studies [12], we have identified the nonscytotoxic window of exposure to H2O2 of hESCs (HUES3 and HUES7) and somatic cells (HS27 and HUVEC), being between 4 and 16 μM H2O2 for Hs27 and HUES cells, and up to 32 μM for HUVEC cells. In this range, we demonstrated that while no modifications of cell number and morphology occurred, a significantly increased level of ROS and lipid peroxidation was observed together with the expression of antioxidant enzymes response.

In a healthy organism during aging, the cellular proteins become increasingly damaged by ROS that induce the formation of the advanced glycation end products (AGEs) and generate ROS in a positive feedback [13, 14]. AGEs are a posttranslational modification generated by a nonenzymatic reaction, between reducing sugars and the amino groups of proteins, known as the “Maillard reaction,” which results in a change of protein structure [15]. This reaction occurs during aging and at an accelerated rate under situations such as hyperglycemia, inflammation, and/or oxidative stress conditions [16], being considered the etiology of various age-related diseases such as diabetes mellitus type 2 (DM2) [17]. Hyperglycaemia is characterized by an increase of oxidative stress biomarkers and cytokine secretion [18] and is accompanied by a decreased activity of the antioxidant systems induced by H2O2 treatment in vitro or by glucose intake in vivo [19]. High glucose environment is considered an important teratogenic factor for congenital malformations [20]; however, it is not yet clear in which way maternal hyperglycaemia and its consequent oxidative stress affects prenatal embryo development [21, 22].

Most AGE researches are performed using representative AGE compounds, like the Nε-carboxymethyl-lysine (CML) [23]. One of the major glycosylation products found in vitro is the CML modification of proteins, and it represents a general marker of both oxidative stress and long-term protein damage in diabetes and aging [24]. AGEs are able to activate intracellular cascades by binding with the AGE receptor (RAGE), which is able to transduce the molecular effects of multiple ligands [25], inducing oxidative stress and proinflammatory signalling responses [19] and mediating its pathological effects [26, 27]. Transmembrane RAGE is a cell-surface membrane protein within the immunoglobulin superfamily, constituted by three domains: a domain necessary for membrane docking, an extracellular ligand-binding domain and a cytosolic domain that is fundamental in the perpetuation of signalling events inside the cell [19]. A splice variant also exists in soluble form called sRAGE [28, 29]. The question of the functional relevance of transmembrane RAGE has become more and more popular in the last years. It is highly expressed in the early embryo at the blastocyst stage [22] and during organogenesis especially in the lung and brain [30]; then, its level decreases in nondiseased adult tissues [31], being low in neurons, endothelial cells, mononuclear phagocytes, and smooth muscle cells [30, 32]. Besides the potential role of RAGE in embryogenesis and aging processes, its physiological function is largely undefined [14]. In pathological settings such as DM, inflammation, tumours, and neurodegeneration, the RAGE expression is higher than in control animal models or human individuals [25]. AGEs and RAGE also play a central role in the pathogenesis of cardiovascular disease (CVD) [33, 34]. Diabetic micro and vascular complications are usually initiated by AGEs through the structural modification and consequent functional alteration of the proteins that are part of the extracellular matrix as well as intracellular signalling molecules. Then, engagement of RAGE with AGEs has been described that induces intracellular ROS generation and afterwards activates mitogen-activated protein kinase and nuclear factor kappa-B (NF-κB) signalling, followed by production and secretion of several profibrotic and inflammatory factors [35]. Generally, RAGE is most often described to induce deleterious effects, and in previous works, the RAGE blocking showed beneficial effects in diverse diseases, suggesting RAGE as pharmaco-therapeutic target. For example, the suppression of RAGE expression by using small interference RNAs technology has been shown to contribute to the reduction of inflammation and apoptosis processes [36]. However, the modifications in receptor activity and the induced negative or positive effects of receptor-mediated AGE signalling during aging process are still to be understood.

Oxidative stress has been described critical for cell viability because the effects of mild or higher oxidation environment influences the regulation of protein production, folding changes, and proteolytic systems’ adjustment. The control of protein degradation in part relies on the ubiquitin-proteasome pathway [37]. Modified proteins such as AGEs are suggested to cause cellular degeneration by forming big aggregates that not only abscond degradation but clog up the proteasomes [38] explaining why damaged and potentially proteasome-susceptible substrates accumulate with time during aging. The structure of the 26S proteasome is responsible for ATP/ubiquitin-mediated proteolysis and consists of two entities: a 20S particle that contains the proteolytic active sites and a 19S regulatory particle [39], which acts as a cap controlling the aperture of the 20S core [40]. In fact, for long time, the ubiquitin 26S/30S proteasome degradation pathway was believed to be the primary route for proteasomal degradation but is now becoming clear that although there is solid evidence that indicates that ubiquitination is involved in some forms of oxidized protein degradation [41], such proteins can also be targeted for degradation directly by the core 20S proteasome, carrying out the proteolytic activities independently of the 19S regulator [42]. Moreover, the 20S proteasome was shown to be more resistant than 26S against oxidative stress and was able to keep its activity even when the conditions induce protein damages [43]. Therefore, the substrates of the 20S proteasome are proteins that have become unfolded, partially or completely, due to mutations, aging, or oxidation [42].

Human ESCs are a valuable tool to study how the pluripotent cells in the human blastocyst stage react to an adverse environment, during the critical preimplantation window when alterations like oxidative stress can lead to future disorders, according to the Developmental Origins of Health and Disease theory (DOHaD) [44]. It has been demonstrated that in comparison with differentiated cells, murine ES cells exhibit a superior capacity to deal with external oxidative stress [45]. While the levels of telomerase activity are higher in hESC in order to protect from telomere shortening, the levels of ROS and DNA damage increase with differentiation process, suggesting that the somatic cells protect less their genome compared with their undifferentiated counterparts [46]. Interestingly, mouse ES cells contain also relatively high levels of AGEs as the early preimplantation embryo. However, the role of AGEs in ES cells and in the early mammal embryo is not understood, but it is known that they are efficiently eliminated during differentiation [47]. In murine, ESC has been demonstrated that removal of oxidatively damaged proteins is observed from the first signs of cell fate determination by an upregulation of the PA28αβ regulator [48].

Therefore, the objective of this study is to analyse and compare the response against oxidative stress in terms of AGE and RAGE levels between embryonic and differentiated somatic cells. We have applied a previously described noncytotoxic H2O2 treatment to generate an oxidative stress status identified by an increase of ROS [12]. Then, we have analysed the levels of AGEs and RAGE in two treated hES cells and in two treated somatic cell lines, revealing that oxidative stress affects the AGE accumulation and RAGE expression in a different way in embryonic versus differentiated cell lines. To unravel this differential response, further analysis during ES cell differentiation and in differentiated derivatives confirms that a process of efficient reduction of damaged proteins takes place in association with elevated 20S proteasomal activity.

2. Materials and Methods

2.1. Cell Culture

Human embryonic stem cells (HUES3 and HUES7 cell lines, obtained from Harvard Stem Cells Institute) [49] were first cultured on a feeder layer of mouse embryonic fibroblasts (MEFs) inactivated by mitomycin C (Sigma-Aldrich, Milan, Italy) in KO-DMEM medium (Gibco Invitrogen, Milan, Italy) supplemented with 10% serum replacement (Gibco Invitrogen, Milan, Italy), 4.3 mg/ml bovine serum albumin (BSA) (Sigma-Aldrich, Milan, Italy), 2 mM glutamine (L-alanyl-L-glutamine, Sigma-Aldrich, Milan, Italy), 1% nonessential amino acids (Gibco Invitrogen, Milan, Italy), 0.055 mM beta-mercaptoethanol (Gibco Invitrogen, Milan, Italy), 63 mg/ml penicillin, 70 mg/ml streptomycin, and 10 ng/ml bFGF (Pepro-tech, Milan, Italy). To perform the experiments, hESCs were adapted to grow in feeder-free conditions in mTeSR™1 medium (Stemcell Technologies, obtained from Voden medical instruments, Milan, Italy). The cells were passaged 1 : 4 with PBS/EDTA every 3 days, and the medium was changed daily.

Human fibroblasts (Hs27 cell line, obtained from Biobanking of Veterinary Resources, IZSLER, Brescia, Italy) were cultured in Dulbecco’s Modified Eagle Medium (DMEM, high glucose, GlutaMAX™ supplement, Gibco Invitrogen, Milan, Italy), supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich, St. Louis, MO, USA). Human umbilical vein endothelial cells (HUVEC line, obtained from Biobanking of Veterinary Resources, IZSLER, Brescia, Italy) were cultured in Medium-200 supplemented with 2% low serum growth supplement (Gibco Invitrogen, Milan, Italy). Cells were passaged 1 : 3 by 0.05% trypsin/EDTA incubation at 37°C for 5 minutes (min) every 4 days.

The exposure to H2O2 started 24 hours (h) after plating, and medium was changed daily during the following 72 h, ending at day 4 after plating. Hs27 and HUVEC cells were grown in 60 mm dishes and HUES cells in 24-well plates. For immunofluorescence, detection cells were seeded on 6 mm diameter glass cover slides, and to reach the optimal cell confluence after 72 h treatment, cells were plated at different concentrations: somatic cells (Hs27 and HUVEC) were plated at 60.000 cells/ml and hESCs (HUES3 and HUES7) at 40.000 cells/ml. At the end of the treatment, cell pellets were snap-frozen for proteomic analysis and RT-qPCR or fixed in PFA (4% in PBS) for immunocytochemistry.

Replicates were performed on samples that were obtained from at least two different cell stocks that were frozen at different times and after a different number of subculture passage.

Proliferating neural precursors cells derived according to [50] were cultured on matrigel-coated dishes in DMEM-F12 medium supplemented with 2 mM glutamine, 0.6% glucose, 5 mM HEPES, 3 mM sodium bicarbonate, 60 μM putrescine, 25 μg/ml insulin, 100 μg/ml transferrin, 20 nM progesterone, 30 nM sodium selenite, 10 ng/ml bFGF, and 2 μg/ml heparin. Cells were passaged 1 : 2 twice per week.

2.2. In Vitro Cardiac Differentiation from hESCs (HUES7) on Feeder-Free Conditions

An established cardiac differentiation protocol from feeder-free human-induced pluripotent stem cells [51] has been utilized to differentiate hES HUES7 cell line. Embryoid body (EB) formation was initiated by harvesting HUES7 cells on feeder-free medium and transferring them to EB20 medium, which contains DMEM/F12 supplemented with 20% of fetal bovine serum albumin (BSA) (Sigma-Aldrich, Milan, Italy), 0.1 mM glutamine (Sigma-Aldrich, Milan, Italy), 0.1 mM nonessential amino acids (Gibco Invitrogen, Milan, Italy), 0.055 mM beta-mercaptoethanol (Gibco Invitrogen, Milan, Italy), 50 units/ml penicillin, 50 mg/ml streptomycin, and 50 μg/ml of L-ascorbic acid (Sigma-Aldrich, Milan, Italy). After 3 days of culture, the medium was changed and at day 7 the EBs were collected for further analysis or transferred into gelatin-coated plates and cultured until the EBs were adhered to the plate tightly. Medium was changed twice per week, and contracting areas appeared after approximately 15 days. When the spontaneous contraction started, the medium was switched to EB2 medium, which was prepared as EB20 medium with 2% of FBS instead. From this moment, the medium was changed twice per week for two weeks more when cells were collected for further experiments.

2.3. Protein Preparation and AGE Detection by Slot Blot Analysis

For protein extraction, cell pellets from three independent replicates were dissolved separately in RIPA lysis buffer (PBS pH 7.5, 0.5% wt/vol sodium deoxycholate, 1% vol/vol NP-40, and 0.1% wt/vol SDS) with 15% of protease inhibitors (Complete Mini EDTA free, Roche, Milan, Italy) and 10% of phosphatase inhibitors (PhosSTOP, Roche, Milan, Italy), and homogenised with a syringe (26G—Terumo, Milan, Italy). After incubation on ice for 30 min, the samples were centrifuged at 14.000 rpm at 4°C for 20 min. In a new tube was collected the supernatant fraction, and the protein concentration was determined using a BCA Protein Assay kit (Pierce). Protein samples were stored at −80°C until use for slot blot or western blot analysis.

Slot blot analyses were performed on three independent replicates with 25 μg protein for each. Denatured protein samples were heated for 10 min at 80° and spotted onto a nitrocellulose blotting membrane (GE Healthcare, Life Sciences, Amersham Protran) using a slot blot apparatus (TransBlot Turbo BioRad, Milan, Italy). The protein load was detected by Ponceau S staining. After blocking with Western Blocking Reagent Solution (Roche, Milan, Italy) for 1 h at room temperature (RT), the membranes were incubated with the monoclonal mouse antibody against the advanced glycation endproduct Nε-carboxymethyl-lysine (CML), the monoclonal IgG mouse antipentosidine antibody, and the monoclonal IgG antiargpyrimidine antibody, all from Biologo (Kassel, Germany), 1 : 100 in 5% milk powder and overnight at 4°C. Then, the samples were washed three times with TBS+ 1% Tween 20 (TBS-T) pH 7.5 for 5 min and incubated with a goat anti-mouse secondary antibody for 2 h (1 : 4000, Millipore, Milan, Italy) at RT. The immunoreactive signal was visualized by Luminata Forte Western HRP substrate (Millipore, Milan, Italy), and the quantification was performed measuring the intensity of the bands using ImageJ software. Protein modification rate was determined as the ratio of protein load (Ponceau) and the slot intensity by antibody reaction. The H2O2 condition values were normalized to the untreated control (CTR).

The anti-CML antibody was tested as described in Supplementary Figure S available online at https://doi.org/10.1155/2017/4240136, demonstrating its specificity. The production and specificity of mouse monoclonal IgG antiargpyrimidine antibody (clone 6B) was described previously [52]; and the specificity of monoclonal IgG antipentosidine (clone PEN-12) was controlled using competitive ELISA too, performed by the providing company (TansGenic Inc., Kumatomoto, Japan) as indicated in product description. Furthermore, the antipentosidine (clone PEN-12) was used by other authors for identification of pentosidine-modified proteins by Western blotting [53].

2.4. Western Blot Analysis

Western blot analysis was performed on three independent replicates with 25 μg/lane protein loads into SDS polyacrylamide gel (Mini-Protean TGX, Stain-free gels 10%, BioRad, Milan, Italy) and transferred with a Trans Blot Turbo machine (BioRad, Milan, Italy) to a nitrocellulose blotting membrane (GE Healthcare, Life Sciences, Amersham Protran) followed by immunoblotting. Membranes were blocked with Western Blocking Reagent Solution (Roche, Milan, Italy) for 1 h at RT. The membranes were then incubated overnight at 4°C with the goat polyclonal antibody against C-terminus of RAGE (1 : 100, sc-8229, Santa Cruz Biotechnologies Inc., Milan, Italy). Samples were washed three times with TBS-T for 5 min and then incubated with an anti-goat IgG secondary antibody for 2 h (1 : 250, Millipore, Milan) at RT.

The immunoreactive signal was visualized by Luminata Forte Western HRP substrate (Millipore, Milan, Italy). Quantification was performed measuring the intensity of the bands using ImageJ software. Membranes were stripped in harsh solution (10% SDS, Tris HCl 0.5 M pH 6.8 and 0.7% β-mercaptoethanol in H2O) during 50 min at 50°C, washed three times with TBS-T for 5 min and left blocking overnight at 4°C. The membranes were then incubated with the mouse monoclonal antibody against β-actin (1 : 35.000, ab6276, abcam) for 2 h at RT. After that, membranes were washed three times with TBS-T for 5 min and then incubated with an anti-mouse IgG secondary antibody for 1 h (1 : 4000, Millipore, Milan) at RT. The same membranes were probed for both target protein and loading control. Protein modification rate was calculated as the ratio between β-actin signal and the RAGE intensity by antibody reaction. The H2O2 condition values were normalized to the untreated control (CTR).

2.5. 20S Proteasome Activity Assay

Cells from three independent experiments were lysed separately using RIPA lysis buffer (PBS pH 7.5, 1% vol/vol NP-40, 0.5% wt/vol sodium deoxycholate, and 0.1% wt/vol SDS) and homogenised with a syringe (26G—Terumo, Milan, Italy). After incubation on ice for 30 min, the samples were centrifuged at 14.000 rpm at 4°C for 20 min. In a new tube, the supernatant fraction was collected and the protein concentration was determined using a Pierce BCA Protein Assay kit (Thermo Scientific, Milan, Italy). The proteasomal activity was measured using the 20S Proteasome Activity Assay kit according to the manufacturer’s instructions (APT280, Chemicon, Millipore). Briefly, the lysates (25 μg of each protein sample) were incubated with the fluorogenic substrate LLVY-AMC (a fluorophore 7-amino-4-methylcoumarin [AMC] bound with LLVY peptide) in a 96-well fluorometer plate at 37°C for 1.5 h. LLVY is a substrate identified and cleaved by the 20S proteasome. After LLVY chymotryptic cleavage by the 20S proteasome, AMC is released and emits fluorescence that can be read in a fluorometer by using a 380/460 nm excitation and emission filters, in this case in a Tecan Infinite F200 PRO microplate reader (Tecan Italia srl, Cernusco sul Naviglio, Italy). Proteasome activity is expressed as relative fluorescent units (RFU) of the inhibited fraction of AMC signal with Lactacystin 20S proteasome inhibitor of the β5 subunit [54] provided in the kit.

2.6. RNA Isolation, cDNA Synthesis, and qPCR

RNA was extracted from control and treated cells, from three different independent replicates, using the RNeasy Mini Kit (Qiagen, Milan, Italy) following the manufacturer’s instructions. Immediately after extraction, the reverse transcription reaction was carried out with iScriptTM cDNA Synthesis Kit (Bio-Rad, Milan, Italy) following the manufacturer’s instructions. Tubes were first incubated at 25°C for 5 min and then at 42°C for 30 min to allow the reverse transcription of mRNA, followed by 85°C for 5 min to denature the enzyme.

The amount of RAGE and cardiac validation gene transcripts was determined by real-time quantitative PCR (RT-qPCR). Three-control cDNA replicates and three replicates of each treatment condition (4, 8, 16, and 32 μM of H2O2) were conducted for all genes of interest. PCR was performed with the PCR mix iTaqTM Universal SYBR Green Supermix (Bio-Rad, Milan, Italy) containing the specific primers (Supplementary Table T) in a MyiQ Real-Time PCR Detection System (Bio-Rad, Milan, Italy). Data were analysed with the iQ Optical System Software (Bio-Rad) by the ddCt method. 18S was used as housekeeping reference gene. Expression amounts of the examined genes were normalized to the untreated control, CTR.

2.7. Immunofluorescence of CML and RAGE

In order to localize the CML and RAGE, cells grown at glass cover slides were washed once with PBS and fixed in 4% paraformaldehyde (VWR, Milan, Italy) for 30 min at RT. Then, they were permeabilized by incubation in 0.5% Triton (Sigma, Milan, Italy) in PBS for 15 min at RT and blocked in 10% chicken serum (Sigma, Milan, Italy) in PBS for 1 hour at RT. After that, cells were incubated 2 h at RT with the monoclonal mouse antibody against CML (1 : 100, Biologo, Kassel, Germany) and goat polyclonal antibody against RAGE (1 : 100, sc-8229, Santa Cruz Biotechnologies Inc, Milan, Italy). Following incubation, cells were washed three times and incubated with secondary antibodies 1 : 200 Fitc anti-mouse and 1 : 150 Texas-Red anti-goat (Jackson ImmunoResearch, Milan, Italy) for 1.5 hours in the dark at RT. Finally, cells were incubated with 5 μg/ml Hoechst 33342 (Sigma, Milan, Italy) for 15 min in the dark at RT and washed three times in PBS and mounted with Citifluor (Citifluor Ltd., London, UK). Slides were observed by fluorescence microscopy (Nikon Eclipse 80i). Negative controls were performed with omission of the primary antibody before secondary antibody addition.

2.8. Statistical Analysis

All values are expressed as mean ± standard deviation (SD) and were obtained from three separate replicates. Statistical analysis was assessed by one-way ANOVA and Tukey’s post hoc test for multiple comparisons. All statistical calculations were computed using GraphPad PRISM software version 6 (GraphPad Software, San Diego, CA), indicates significant differences, val ≤0.05; val ≤0.01; val ≤0.001, and val ≤0.0001.

3. Results

3.1. Detection of Advanced Glycation End-Product Proteins in Treated hES and Somatic Cell Lines

In a previous work [12], we developed a novel in vitro model to analyse the effects of oxidative stress and the antioxidant response against reactive oxygen species (ROS) on embryonic stem cells in comparison with somatic cells, demonstrating that the nonlethal doses of H2O2 resulted in an increase in oxidative stress in treated cells. To evaluate the nominal concentration-effect relationship for the cytotoxic action of H2O2, human somatic cells (Hs27 and HUVEC) and embryonic stem (HUES3 and HUES7) cell lines were exposed to rising concentrations of H2O2 between 4 and 768 μM during 72 h and cell viability was analysed by AlamarBlue® reduction and normalized to the nontreated control samples of each cell line (Figure 1(a)).

To determine the AGE status of the cells under oxidative stress conditions, we quantified specific protein-bound AGEs by slot blot analysis in three independent experiments of treated HUES3 and Hs27 cell lines, with specific antibodies against pentosidine, argpypyrimidine, and Nε-carboxymethyl-lysine (CML). Pentosidine and argpypyrimidine levels’ analysis showed no differences between control and treated cells (data not shown). Likewise, the slot blot analysis revealed no differences in CML protein-bound between control HUES3 and HUES7 and H2O2 treated cells (Figures 1(c) and 1(d)). On the contrary, somatic cells, Hs27 and HUVEC cell lines, showed a significant increase of CML levels on treated cells by noncytotoxic H2O2 concentrations, between 8 and 16 μM for Hs27 (Figure 1(e)) and between 16 and 32 μM compared with the lowest H2O2 concentration (4 μM) for HUVEC (Figure 1(f)).

Immunocytochemical fluorescence staining of the cells showed that CML detection was mainly present in the cytoplasm of HUES lines, and it confirmed no differences between control and treated cells for HUES lines (Supplementary Figures S and S). A very low signal of CML in nontreated somatic cells was slightly increased in terms of fluorescence intensity in somatic H2O2-treated cells.

3.2. Detection of RAGE by Western Blotting and ICC in Treated hES and Somatic Cell Lines

To clear up the potential effects of oxidative stress at noncytotoxic concentrations on RAGE levels, the global receptor levels were examined by western blot. The RAGE levels were evaluated in three independent experiments. Representative outcomes with an estimation of band intensity and graphical global results are shown in Figure 2. RAGE levels increased significantly after 72 h of H2O2 exposure in both hESCs, between 4 and 16 μM in HUES3 and between 4 and 8 μM in HUES7 (Figures 2(A) and 2(B)). On the contrary, somatic cells did not show any differences in terms of RAGE levels between control cells and H2O2 treatment (Figures 2(C) and 2(D)).

Immunocytochemistry confirmed the differences between control and treated cells on hESCs (Supplementary Figures S and S). In somatic cells, the signal detected by immunocytochemistry for CML was very low, so it does not allow to show differences between the controls and the different H2O2 concentrations.

3.3. Detection of mRNA RAGE Expression Levels in Treated Cells with Noncytotoxic H2O2 Concentrations

To further characterize the levels of RAGE under oxidative stress conditions, we analysed its gene expression by real-time quantitative PCR on undifferentiated and differentiated cell lines treated with noncytotoxic H2O2 concentrations. HUES3 and HUES7 cell lines showed a significant increase of RAGE mRNA levels in treated cells at 8 μM for HUES3 (Figure 2(A)) and between 4 and 16 μM for HUES7 (Figure 2(B)). In contrast, somatic cells did not show any differences in terms of RAGE gene expression between control cells and H2O2 treatment (Figures 2(C) and 2(D)). These data coincide with western blot RAGE analysis results.

3.4. Neural and Cardiac Differentiation from hES Cells on Feeder-Free Conditions, as a Strategy to Follow-Up CML and RAGE Levels during Development

To unravel the mechanisms of the differential accumulation of CML and RAGE between embryonic and somatic cells, and in attempt to generate accurate cell models that recapitulate the pathophysiological features of the oxidative stress effects during the embryo development, we induced hES differentiation in two different cell types. We used human neural precursors and neurons derived from hESC in previous work [50]. Since AGEs and RAGE play a central role in the pathogenesis of cardiovascular disease, as previously described [34], we also asked if ES-derived cardiomyocytes have different CML and RAGE basal levels than other differentiated cell lines. To generate functional cardiomyocytes from hES cells line on feeder-free conditions (Figures 3(b) and 3(c)), we follow a protocol through embryoid body (EB) formation (Figures 3(d) and 3(e)) combined with a treatment with a known promoter of cardiac differentiation, the ascorbic acid [51]. The yield of this differentiation protocol varied according to the hESC line, being HUES7 cell line the most successfully differentiated one in comparison with HUES3 and, therefore, the cell line chosen to follow this cardiac differentiation experiments. Spontaneously beating areas of variable size, morphology and pulse rate appeared around 20 days of differentiation (Figures 3(f) and 3(g)). In the same area, we observed cardiomyocytes at different degrees of maturation. We evaluated the temporal gene expression pattern associated with this differentiation process. Figure 4(a) display the real-time PCR experiments, which show that differentiation was characterized by an initial decrease, at the embryoid body stage, in the expression of undifferentiated pluripotent markers (OCT4 and NANOG). Earliest cardiomyogenesis is linked with a peak in the expression of primitive streak, mesoderm, and cardiomesoderm markers like Brachyury and MESP1 at 7 days of differentiation. After this first event, an increase in the expression of cardiac progenitor markers, such as ISL-1, and cardiac-associated transcription factors nKx2-5, MEF2-C, and GATA4, occurs. Finally, we observed the expression of cardiac-specific structural genes, such as sarcomeric-related proteins (CTNNI) and ion channel proteins (CACNA-1C).

3.5. The Levels of CML and RAGE Are Diminished during Differentiation

To determine the basal levels of AGEs and their receptor, at diverse differentiation stages, protein extracts made from undifferentiated and differentiated cells as described above were analysed for the content of CML and RAGE by slot and western blot.

The detection of CML demonstrated that cells that had entered on differentiation displayed lower levels of this AGE than undifferentiated cell lines, being more evident in the cardiac embryoid bodies than in the neural precursors, but decreasing to similar level in cardiomyocytes, neurons, fibroblasts, and endothelial cells (Figure 4(a)). This drop in glycated proteins cannot be explained simply by a dilution of damaged proteins since the undifferentiated embryonic stem cells have a doubling time shorter than their differentiated progenies. In fact, glycated proteins are not eliminated during continuous passages of the undifferentiated and dividing ES cells.

RAGE levels were high in undifferentiated ES cells and decreased upon differentiation (Figure 4(b)). However, cardiac embryoid bodies seemed more similar to their undifferentiated precursors than to the neural precursors, but RAGE level in their differentiated progenies, as in fibroblast and endothelial cells decreased similarly to the CML. Since differentiation process is accompanied by alterations in cellular proteome and cell morphology, we considered the possibility that the reduction in glycated proteins and their receptor could be produced by a reduction in the concentration of specific proteins and not by an elimination of damaged proteins. The lower molecular weight bands present in HUES7 and cardiomyocyte cell protein extracts can be explained by the alternative splicing or cleavage posttranslationally of RAGE [55]. Western blot analysis demonstrated that the overall concentration of protein (β-actin) did not change appreciably during differentiation, indicating that the reduction in CML-modified proteins is not a reduction in overall protein modifications. The decrease may result from minor modification of specific proteins and from a lower expression of modifiable, differentially expressed proteins (Figure 4(b)).

Differentiation of hES cells results in an increase in a 20S proteasomal activity.

Previous works have demonstrated the ability of various cell lines to degrade selectively oxidated proteins and that an increase of intracellular proteolysis correlates with mild oxidative stress status [56]. The primary structure responsible for the degradation of oxidatively damaged proteins in the cytosol and nuclei of mammalian cells is the 20S proteasome [39]. To determine whether the reduction in protein damage, in terms of CML and RAGE levels, upon differentiation was concomitant with altered 20S proteasome, its activity was examined using a proteasome activity assay with a fluorescent substrate LLVY-AMC.

This analysis shows that 20S proteasomal activity augments drastically upon differentiation of ES cells (Figure 4(c)). The significant increase of 20S proteasomal activity is shown after 7 days of differentiation at the embryoid body stage of cardiac differentiation, and even more in the differentiated progenies. Differentiation of hES cells support previous results showing a substantial increase in the cells’ capacity to degrade oxidatively damaged proteins, coincidently with the decreased levels of CML, and their receptor RAGE [47]. Thus, we confirm that 20S proteasome activity is dynamic and directly activated by oxidants, such as hydrogen peroxide, which induces an enhanced resistance to protein damage and increase the proteolytic removal of damaged proteins [39].

3.6. The mRNA RAGE Expression Diminishes during Differentiation

To confirm if the RAGE levels decrease during differentiation in basal conditions, we next examined the mRNA RAGE levels by quantitative real-time PCR in ES cell lines, in their differentiated progenies and on the somatic cell lines Hs27 and HUVEC. Gene expression analysis revealed that RAGE is highly expressed in ES cells and physiologically decreases during differentiation (Figure 5(a)) in agreement with its role during embryogenesis, being crucial among others for neural development and cardiac differentiation (Figure 5(b)).

4. Discussion

For decades, scientists have used cell culture to analyse the effect of oxidative stress, providing a wide body of literature with sometime controversial outcomes. During the last years, hypotheses that relate oxidative stress with a wide range of disorders have gained strength. It has been linked with neurodegeneration, diabetes, cardiovascular diseases, reproductive disorders like pre-eclampsia, and aging [26], but the underlying mechanisms are still unknown.

Protein glycation is an indicator of oxidative damage, and the levels of AGEs increase considerably during aging physiological process in animals [57]. Although relevance of AGEs in the pluripotent embryonic stages remains to be clarified, since the accumulation in the embryo is not a consequence of adverse environment, it can be assumed that the low RAGE expression in oocytes and preimplantation embryos prior to blastocyst stage [14] avoid the detrimental effects of AGE-RAGE interaction. Therefore, in our oxidative stress treatment, we incubated both embryonic and somatic cells with different H2O2 concentrations for 72 h where no effect on cellular viability or proliferation was observed, meanwhile, on the contrary, significant increase in terms of intracellular ROS accumulation and lipid peroxidation has been demonstrated [12].

Several studies proposed that the damaging effect of AGEs is mainly induced by RAGE signalling through a positive feedback increasing inflammatory processes and ROS formation [26]. Moreover, RAGE-ligand interaction leads to an increase in the expression of RAGE itself and its accumulation has been described as an inductor of inflammation in diabetic animal models through NF-kβ [25]. However, it should be considered that the relevance of AGE-RAGE interactions is still under discussion [58], and the potential problem with these analyses is the nonsimultaneous measure of AGE and RAGE levels in the same experimental context [59]. Our study provides new insights about consequences of an oxidative stress environment during the embryonic preimplantation period by analysing both AGE and RAGE levels in undifferentiated hES and then during their differentiation in somatic cells. The way in which ESCs respond to oxidative stress is still largely unexplored. Although other authors have reported that ESCs are more resistant to oxidative stress than their differentiated fibroblastic progenies [45, 46, 60], we have observed the toxic effect of H2O2 on cell viability at similar concentrations in both Hs27 and hESCs. However, in terms of AGE and RAGE accumulation, we have seen significant differences between embryonic and somatic cells. Our results confirm that oxidative stress induces an increase of RAGE levels in hESC, in agreement with previous studies in which an adverse maternal preimplantation environment was correlated with an increase in RAGE expression [22]. Curiously, this elevated RAGE mRNA expression does not imply an evident increase of CML; according to the literature, the stability of CML under oxidative stress conditions is probably due to the high basal plateau in embryonic pluripotent cells [47]. On the contrary, fibroblasts and endothelial cells exposed to H2O2 showed a significant increase of CML levels but not in RAGE expression and of protein amount.

It has been proposed that the defensive mechanisms could be more active in cell types whose natural history is associated with acute environmental variations and, particularly, in cells that carry a disproportionate sensitivity and load in maintaining homeostasis for the entire organism in response to a particular stress [61]. In our study, we can hypothesize that HUVEC showed higher resistance to H2O2 exposure because these cell types in vivo are continuously exposed to shear stress, which has an important impact on cellular metabolism, structure, and function [62], ultimately making them stronger against damage caused by H2O2 and potentially more active in its elimination. Meanwhile, regarding AGE-RAGE in ES cells, a possible hypothesis is that organisms would invest in a different way in stress-response and protective and corrective mechanisms at the beginning of the developmental process compared to later phases, for the simple reason that the effects of abnormalities are more harmful in the initial moments of the developmental process than at the later stages [44]. In ES cells, AGEs are constitutively present but RAGE expression is not high enough at control conditions to increase the risk of oxidative mechanisms. It is the further increase of CML, induced by H2O2 treatment, that triggers the activation of RAGE and therefore inducing ROS production. This peculiar regulation of the AGE-RAGE system could provide a mechanistic hypothesis to explain why adverse uterine environments, such as those occurring in diabetic mothers [22], and ART, may negatively affect the embryo quality and induce long-term effects [44].

The source of the observed AGEs in the early embryo pluripotent stem cells is unclear, but there are important considerations to be taken into account: generally, the production of offspring in mammals is coincident with the initial to middle stages of the organism’s life cycle, that means that it happens when the overall oxidative damage in the organism is still low [32]. Nonetheless, our results show that early embryonic development steps are accompanied by a drastic reduction of AGE-modified proteins, supporting previous works [47]. AGE formation, especially due to glucose reactions, is a very slow process, and moreover, AGE modifications have previously been shown also in preimplantation mice [47] and rabbit embryos [22] and foetuses of rats [63], it can be hypothesized that the AGE accumulation observed in the inner cell mass of the blastocyst from where ES cells originate derives in part from the progressive build-up of modified proteins starting in germ cells and continuing in oocytes [22] but also could be the result of yet unknown mechanisms that make ES cells have a higher levels that change upon differentiation. To unravel this fact, the analysis of glycation products during neural and cardiac differentiation process has been crucial and allowed us to confirm that the AGE and RAGE levels decrease progressively during organism development.

Several promising studies have shown that elevated levels of RAGE are associated with higher incidence of cardiovascular disease [26] or all-cause mortality in diabetical complications [32]. Indeed, it has been described that blocking the signal transduction of RAGE could be an optimal way to prevent the damage effects of oxidative stress, especially in situations of chronic disease [64, 65]. Pluripotent stem cells have been shown to possess the potential to differentiate spontaneously into CMs, although the efficiency is low, and it depends a lot on each cell line [51]. The aggregation process into EBs mimics the natural developmental course, being possible to generate the physiological tridimensional environment in which the paracrine signals have a key role. Furthermore, with the presence of ascorbic acid in the media, we boosted the cardiac differentiation of pluripotent cells and, as well as, we enhanced their structural characteristics and functional maturation activity [66]. Through this protocol of cardiac differentiation, we studied whether cardiomyocyte-like cells present different basal levels of AGE and RAGE than other somatic cell lines, such as neurons, fibroblast, or endothelial cells, hypothetically turning the cardiomyocytes more sensitive in a hyperglycemic environment. We have not seen any difference in terms of basal CML and RAGE mRNA expression and protein accumulation in comparison with other differentiated cell lines. An explanation of our results could be the still immature state of cardiomyocytes compared to fully differentiated adult cardiac cells [67]; but further experiments should be made for the more accurate determination of the underlying reasons to explain that elevated levels of RAGE are associated with a high incidence of cardiovascular disease. In this line, there are still critical questions that remain to be resolved, so RAGE silencing experiments are planned to a greater understanding of the implications of RAGE on physiological processes.

In this study, we have shown that the low levels of damaged proteins in somatic cells are concurrent with an elevated activity of the 20S proteasome, a fact that has been described essential for the degradation of oxidatively damaged proteins in vivo and in vitro [39]. We also showed that differentiating ES cells from established cell lines cultured in vitro display an efficient removal system of damaged proteins and a simultaneously higher 20S proteasome activity, supporting previous results that demonstrate the elimination of oxidatively damaged proteins occurs during normal embryonic development in vivo [47, 48]. Unraveling this mechanism could help to understand the embryonic development process and also help to describe the machinery involved in the aging process, answering to the question of why the differentiated cells invest less in counteracting the gradual accumulation of oxidatively damaged proteins. It has been demonstrated that in vitro 20S can be also controlled by regulators like SDS treatment, opening the structure of 20S and enabling peptide hydrolysis of 20S and therefore its activation, suggesting that all cell types have an equivalent number of 20S particles, because no significant differences in chymotrypsin-like activity were found among the different cells when SDS was added [40]. However, unlike the extensive knowledge acquired over the years respecting the protein degradation process by the 26S proteasome, being described that hESCs have increased levels of the 19S proteasome subunit and a corresponding increased assembly of the 26S/30S proteasome [40], relatively little is known about 20S-mediated proteolysis control.

Alternatively to the 19S particle, the alpha rings of the 20S core can interact, among others, with the cytoplasmic PA28αβ (11S) regulator [48]. Moreover, a special conformation of the core proteasome is constituted by replacing the proteolytically catalytic β1, β2, and β5 subunits with β1i, β2i, and β5i subunits, thus forming the immunoproteasome, which has been shown, together with the 20S and PA28αβ, to be involved in the adaptation and response to oxidative stress [68]. The analysis of these proteasome structures and regulators is planned for next immediate experiments to better understand their protective role against protein oxidation and during embryogenesis [69]. For the moment, in view of the present results, we can hypothesize that the incorrect functioning of the 20S proteasome leads to the formation of oxidized protein aggregates during cell differentiation.

In conclusion, in this work, we provide a comparative analysis of changes in CML advanced glycation end product and RAGE levels in human embryonic stem cells versus somatic cells upon 72 hours oxidative stress. The cells were exposed to H2O2 within the noncytotoxic range. Our data reveal that embryonic cells accumulate CML and RAGE under oxidative stress conditions in a different way than somatic cells. Both cell models differ in the basal levels of glycation products, making them a unique model to study the consequence of an oxidative environment on early embryonic cells. Our results confirm the presence of an efficient reduction process of glycated-damaged proteins in hESC, which coincides with a strongly elevated 20S proteasome activity, which has previously been seen in mES cells [47]. The subtle implications of an exposure to oxidative stress during embryonic development are still largely unknown in humans and remain to be elucidated. However, the findings reported here could be a basis to aid the identification of antioxidant treatments for improving embryo culture conditions.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.


HUES3 and HUES7 cells were kindly provided by D. Melton from Harvard Stem Cells Institute under a specific Material Transfer Agreement to our colleague Professor Cesare Galli. The technical support of Gabriella Crotti and Paola Turini is greatly acknowledged. This work was supported by the European Commission through the EpiHealthNet Marie Curie ITN Project (no. 317146-FP7-People-2012-ITN), the Epihealth project EU FP7 (no. 278418), the COST BM1308 SALAAM project, and the German Research Foundation (ProMoAge 2155).

Supplementary Materials

Supplementary figure S1. Quality control of CML antibody specificity. For testing the specificity of the CML antibody human keratin was treated either with methylglyoxal (inducer of argpyrimidine and pentosidine, in lane 1) or glyoxal (inducer of CML, in lane 2). A. Shows the amidoblack staining of the membrane after the blot as loading control. M; molecular weight marker. B. Shows the immunodetection using the anti-CML antibody. As expected only signals in the sample treated with glyoxal were detected demonstrating the specificity of the antibody. Supplementary figure S2. Immunocytochemical analysis of CML and RAGE in control and H2O2-treated HUES3 cells. 24 h post plating cells were treated for 2 hours with increasing concentrations of H2O2. Immunofluorescence staining was performed with an anti-CML (green) and an anti-RAGE (red) antibodies; Hoechst 33342 (blue) was used for nuclei localization. H2O2 conditions: CTR, Control non-treated cells (A), 4 μM (B), 8 μM (C), 16 μM (D). Scale bar = 100 μm. Supplementary figure S3. Immunocytochemical analysis of CML and RAGE in control and H2O2-treated HUES7 cells. 24 h post plating cells were treated for 2 hours with increasing concentrations of H2O2. Immunofluorescence staining was performed with an anti-CML (green) and an anti-RAGE (red) antibodies; Hoechst 33342 (blue) was used for nuclei localization. H2O2 conditions: CTR, Control non-treated cells (A), 4 μM (B), 8 μM (C), 16 μM (D). Scale bar = 100 μm. Supplementary Table T1. Primer sequences used for Real-Time PCR amplification.

  1. Supplementary Material


  1. P. Gkogkolou and M. Böhm, “Advanced glycation end products: key players in skin aging?” Dermatoendocrinology, vol. 4, no. 3, pp. 259–270, 2012. View at: Publisher Site | Google Scholar
  2. D. Harman, “Free radical theory of aging: an update: increasing the functional life span,” Annals of the New York Academy of Sciences, vol. 1067, pp. 10–21, 2006. View at: Publisher Site | Google Scholar
  3. S. Sahoo, D. N. Meijles, and P. J. Pagano, “NADPH oxidases: key modulators in aging and age-related cardiovascular diseases?” Clinical Science (London, England), vol. 130, no. 5, pp. 317–335, 2016. View at: Publisher Site | Google Scholar
  4. J. Viña, C. Borrás, and J. Miquel, “Theories of ageing,” IUBMB Life, vol. 59, no. 4-5, pp. 249–254, 2007. View at: Publisher Site | Google Scholar
  5. R. S. Balaban, S. Nemoto, and T. Finkel, “Mitochondria, oxidants, and aging,” Cell, vol. 120, no. 4, pp. 483–495, 2005. View at: Publisher Site | Google Scholar
  6. D. R. Gough and T. G. Cotter, “Hydrogen peroxide: a Jekyll and Hyde signalling molecule,” Cell Death & Disease, vol. 2, article e213, 2011. View at: Publisher Site | Google Scholar
  7. S. Maynard, A. M. Swistowska, J. W. Lee et al., “Human embryonic stem cells have enhanced repair of multiple forms of DNA damage,” Stem Cells, vol. 26, no. 9, pp. 2266–2274, 2008. View at: Publisher Site | Google Scholar
  8. P. Chaudhari, Z. Ye, and Y. Y. Jang, “Roles of reactive oxygen species in the fate of stem cells,” Antioxidants & Redox Signaling, vol. 20, no. 12, pp. 1881–1890, 2014. View at: Publisher Site | Google Scholar
  9. M. Gülden, A. Jess, J. Kammann, E. Maser, and H. Seibert, “Cytotoxic potency of H2O2 in cell cultures: impact of cell concentration and exposure time,” Free Radical Biology and Medicine, vol. 49, no. 8, pp. 1298–1305, 2010. View at: Publisher Site | Google Scholar
  10. J. Duan, J. Duan, Z. Zhang, and T. Tong, “Irreversible cellular senescence induced by prolonged exposure to H2O2 involves DNA-damage-and-repair genes and telomere shortening,” The International Journal of Biochemistry & Cell Biology, vol. 37, no. 7, pp. 1407–1420, 2005. View at: Publisher Site | Google Scholar
  11. Y. L. Guo, S. Chakraborty, S. S. Rajan, R. Wang, and F. Huang, “Effects of oxidative stress on mouse embryonic stem cell proliferation, apoptosis, senescence, and self-renewal,” Stem Cells and Development, vol. 19, no. 9, pp. 1321–1331, 2010. View at: Publisher Site | Google Scholar
  12. M. Barandalla, S. Colleoni, and G. Lazzari, “Differential response of human embryonic stem and somatic cells to non-cytotoxic hydrogen peroxide exposure: an attempt to model in vitro the effects of oxidative stress on the early embryo,” Cell and Developmental Biology, vol. 5, no. 2, 2016. View at: Publisher Site | Google Scholar
  13. R. Singh, A. Barden, T. Mori, and L. Beilin, “Advanced glycation end-products: a review,” Diabetologia, vol. 44, no. 2, pp. 129–146, 2001. View at: Publisher Site | Google Scholar
  14. C. Ott, K. Jacobs, E. Haucke, A. Navarrete Santos, T. Grune, and A. Simm, “Role of advanced glycation end products in cellular signaling,” Redox Biology, vol. 2, pp. 411–429, 2014. View at: Publisher Site | Google Scholar
  15. P. Younessi and A. Yoonessi, “Advanced glycation end-products and their receptor-mediated roles: inflammation and oxidative stress,” Iran Journal of Medical Sciences, vol. 36, no. 3, pp. 154–166, 2011. View at: Google Scholar
  16. S. Yamagishi, K. Fukami, and T. Matsui, “Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: a novel marker of vascular complications in high-risk patients for cardiovascular disease,” International Journal of Cardiology, vol. 185, pp. 263–268, 2015. View at: Publisher Site | Google Scholar
  17. M. E. Cooper, “Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease,” American Journal of Hypertension, vol. 17, no. 12, Part 2, pp. 31S–38S, 2004. View at: Publisher Site | Google Scholar
  18. K. Esposito, R. Marfella, and D. Giugliano, “Stress hyperglycemia, inflammation, and cardiovascular events,” Diabetes Care, vol. 26, no. 5, pp. 1650-1651, 2003. View at: Google Scholar
  19. A. Negre-Salvayre, R. Salvayre, N. Augé, R. Pamplona, and M. Portero-Otín, “Hyperglycemia and glycation in diabetic complications,” Antioxidants & Redox Signaling, vol. 11, no. 12, pp. 3071–3109, 2009. View at: Publisher Site | Google Scholar
  20. X. Y. Wang, S. Li, G. Wang et al., “High glucose environment inhibits cranial neural crest survival by activating excessive autophagy in the chick embryo,” Scientific Reports, vol. 5, article 18321, 2015. View at: Publisher Site | Google Scholar
  21. N. Corrigan, D. P. Brazil, and F. McAuliffe, “Fetal cardiac effects of maternal hyperglycemia during pregnancy,” Birth Defects Research Part A, Clinical and Molecular Teratology, vol. 85, no. 6, pp. 523–530, 2009. View at: Publisher Site | Google Scholar
  22. E. Haucke, A. Navarrete Santos, A. Simm et al., “Accumulation of advanced glycation end products in the rabbit blastocyst under maternal diabetes,” Reproduction, vol. 148, no. 2, pp. 169–178, 2014. View at: Publisher Site | Google Scholar
  23. K. A. Ahmed, S. Muniandy, and I. S. Ismail, “N(epsilon)-(carboxymethyl)lysine and coronary atherosclerosis-associated low density lipoprotein abnormalities in type 2 diabetes: current status,” Journal of Clinical Biochemistry and Nutrition, vol. 44, no. 1, pp. 14–27, 2009. View at: Publisher Site | Google Scholar
  24. K. Nowotny, T. Jung, A. Höhn, D. Weber, and T. Grune, “Advanced glycation end products and oxidative stress in type 2 diabetes mellitus,” Biomolecules, vol. 5, no. 1, pp. 194–222, 2015. View at: Publisher Site | Google Scholar
  25. S. F. Yan, R. Ramasamy, and A. M. Schmidt, “The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature,” Circulation Research, vol. 106, no. 5, pp. 842–853, 2010. View at: Publisher Site | Google Scholar
  26. G. Daffu, C. H. de Pozo, K. M. O'Shea, R. Ananthakrishnan, R. Ramasamy, and A. M. Schmidt, “Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond,” International Journal of Molecular Sciences, vol. 14, no. 10, pp. 19891–19910, 2013. View at: Publisher Site | Google Scholar
  27. A. Ejdesjö, S. Brings, T. Fleming, R. G. Fred, P. P. Nawroth, and U. J. Eriksson, “Receptor for advanced glycation end products (RAGE) knockout reduces fetal dysmorphogenesis in murine diabetic pregnancy,” Reproductive Toxicology, vol. 62, pp. 62–70, 2016. View at: Publisher Site | Google Scholar
  28. E. Devangelio, F. Santilli, G. Formoso et al., “Soluble RAGE in type 2 diabetes: association with oxidative stress,” Free Radical Biology and Medicine, vol. 43, no. 4, pp. 511–518, 2007. View at: Publisher Site | Google Scholar
  29. K. Fujisawa, N. Katakami, H. Kaneto et al., “Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes,” Atherosclerosis, vol. 227, no. 2, pp. 425–428, 2013. View at: Publisher Site | Google Scholar
  30. D. R. Winden, N. T. Ferguson, B. R. Bukey et al., “Conditional over-expression of RAGE by embryonic alveolar epithelium compromises the respiratory membrane and impairs endothelial cell differentiation,” Respiratory Research, vol. 14, p. 108, 2013. View at: Publisher Site | Google Scholar
  31. A. Rojas, I. González, E. Morales, R. Pérez-Castro, J. Romero, and H. Figueroa, “Diabetes and cancer: looking at the multiligand/RAGE axis,” World Journal of Diabetes, vol. 2, no. 7, pp. 108–113, 2011. View at: Publisher Site | Google Scholar
  32. P. P. Lizotte, L. E. Hanford, J. J. Enghild, E. Nozik-Grayck, B. L. Giles, and T. D. Oury, “Developmental expression of the receptor for advanced glycation end-products (RAGE) and its response to hyperoxia in the neonatal rat lung,” BMC Developmental Biology, vol. 7, p. 15, 2007. View at: Publisher Site | Google Scholar
  33. A. Goldin, J. A. Beckman, A. M. Schmidt, and M. A. Creager, “Advanced glycation end products: sparking the development of diabetic vascular injury,” Circulation, vol. 114, no. 6, pp. 597–605, 2006. View at: Publisher Site | Google Scholar
  34. A. Z. Kalea, A. M. Schmidt, and B. I. Hudson, “RAGE: a novel biological and genetic marker for vascular disease,” Clinical Science (London, England), vol. 116, no. 8, pp. 621–637, 2009. View at: Publisher Site | Google Scholar
  35. K. Fukami, S. Yamagishi, and S. Okuda, “Role of AGEs-RAGE system in cardiovascular disease,” Current Pharmaceutical Design, vol. 20, no. 14, pp. 2395–2402, 2014. View at: Google Scholar
  36. H. Park, S. H. Ku, H. Park et al., “RAGE siRNA-mediated gene silencing provides cardioprotection against ventricular arrhythmias in acute ischemia and reperfusion,” Journal of Controlled Release, vol. 217, pp. 315–326, 2015. View at: Publisher Site | Google Scholar
  37. N. Breusing and T. Grune, “Regulation of proteasome-mediated protein degradation during oxidative stress and aging,” Biological Chemistry, vol. 389, no. 3, pp. 203–209, 2008. View at: Publisher Site | Google Scholar
  38. T. Grune, T. Jung, K. Merker, and K. J. Davies, “Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and “aggresomes” during oxidative stress, aging, and disease,” The International Journal of Biochemistry & Cell Biology, vol. 36, no. 12, pp. 2519–2530, 2004. View at: Publisher Site | Google Scholar
  39. A. M. Pickering and K. J. Davies, “Degradation of damaged proteins: the main function of the 20S proteasome,” Progress in Molecular Biology and Translational Science, vol. 109, pp. 227–248, 2012. View at: Publisher Site | Google Scholar
  40. D. Vilchez, L. Boyer, I. Morantte et al., “Increased proteasome activity in human embryonic stem cells is regulated by PSMD11,” Nature, vol. 489, no. 7415, pp. 304–308, 2012. View at: Publisher Site | Google Scholar
  41. F. Shang and A. Taylor, “Ubiquitin-proteasome pathway and cellular responses to oxidative stress,” Free Radical Biology and Medicine, vol. 51, no. 1, pp. 5–16, 2011. View at: Publisher Site | Google Scholar
  42. G. Ben-Nissan and M. Sharon, “Regulating the 20S proteasome ubiquitin-independent degradation pathway,” Biomolecules, vol. 4, no. 3, pp. 862–884, 2014. View at: Publisher Site | Google Scholar
  43. T. J. Höhn and T. Grune, “The proteasome and the degradation of oxidized proteins: part III-redox regulation of the proteasomal system,” Redox Biology, vol. 2, pp. 388–394, 2014. View at: Publisher Site | Google Scholar
  44. D. J. Barker, “The origins of the developmental origins theory,” Journal of Internal Medicine, vol. 261, no. 5, pp. 412–417, 2007. View at: Publisher Site | Google Scholar
  45. G. Saretzki, L. Armstrong, A. Leake, M. Lako, and T. von Zglinicki, “Stress defense in murine embryonic stem cells is superior to that of various differentiated murine cells,” Stem Cells, vol. 22, no. 6, pp. 962–971, 2004. View at: Publisher Site | Google Scholar
  46. G. Saretzki, T. Walter, S. Atkinson et al., “Downregulation of multiple stress defense mechanisms during differentiation of human embryonic stem cells,” Stem Cells, vol. 26, no. 2, pp. 455–464, 2008. View at: Publisher Site | Google Scholar
  47. M. Hernebring, G. Brolén, H. Aguilaniu, H. Semb, and T. Nyström, “Elimination of damaged proteins during differentiation of embryonic stem cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 20, pp. 7700–7705, 2006. View at: Publisher Site | Google Scholar
  48. M. Hernebring, Å. Fredriksson, M. Liljevald et al., “Removal of damaged proteins during ES cell fate specification requires the proteasome activator PA28,” Scientific Reports, vol. 3, p. 1381, 2013. View at: Publisher Site | Google Scholar
  49. C. A. Cowan, I. Klimanskaya, J. McMahon et al., “Derivation of embryonic stem-cell lines from human blastocysts,” The New England Journal of Medicine, vol. 350, no. 13, pp. 1353–1356, 2004. View at: Publisher Site | Google Scholar
  50. S. Colleoni, C. Galli, S. G. Giannelli et al., “Long-term culture and differentiation of CNS precursors derived from anterior human neural rosettes following exposure to ventralizing factors,” Experimental Cell Research, vol. 316, no. 7, pp. 1148–1158, 2010. View at: Publisher Site | Google Scholar
  51. E. Di Pasquale, B. Song, and G. Condorelli, “Generation of human cardiomyocytes: a differentiation protocol from feeder-free human induced pluripotent stem cells,” Journal of Visualized Experiments, vol. 76, 2013. View at: Publisher Site | Google Scholar
  52. T. Oya, N. Hattori, Y. Mizuno et al., “Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts,” The Journal of Biological Chemistry, vol. 274, no. 26, pp. 18492–18502, 1999. View at: Google Scholar
  53. C. Machahua, A. Montes-Worboys, R. Llatjos et al., “Increased AGE-RAGE ratio in idiopathic pulmonary fibrosis,” Respiratory Research, vol. 17, no. 1, p. 144, 2016. View at: Publisher Site | Google Scholar
  54. A. F. Kisselev and A. L. Goldberg, “Proteasome inhibitors: from research tools to drug candidates,” Chemistry & Biology, vol. 8, no. 8, pp. 739–758, 2001. View at: Google Scholar
  55. R. López-Díez, A. Rastrojo, O. Villate, and B. Aguado, “Complex tissue-specific patterns and distribution of multiple RAGE splice variants in different mammals,” Genome Biology and Evolution, vol. 5, no. 12, pp. 2420–2435, 2013. View at: Publisher Site | Google Scholar
  56. R. Raynes, L. C. Pomatto, and K. J. Davies, “Degradation of oxidized proteins by the proteasome: distinguishing between the 20S, 26S, and immunoproteasome proteolytic pathways,” Molecular Aspects of Medicine, vol. 50, pp. 41–55, 2016. View at: Publisher Site | Google Scholar
  57. R. D. Semba, E. J. Nicklett, and L. Ferrucci, “Does accumulation of advanced glycation end products contribute to the aging phenotype?” The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, vol. 65, no. 9, pp. 963–975, 2010. View at: Publisher Site | Google Scholar
  58. C. Piperi, A. Goumenos, C. Adamopoulos, and A. G. Papavassiliou, “AGE/RAGE signalling regulation by miRNAs: associations with diabetic complications and therapeutic potential,” The International Journal of Biochemistry & Cell Biology, vol. 60, pp. 197–201, 2015. View at: Publisher Site | Google Scholar
  59. C. W. Heizmann, “The mechanism by which dietary AGEs are a risk to human health is via their interaction with RAGE: arguing against the motion,” Molecular Nutrition & Food Research, vol. 51, no. 9, pp. 1116–1119, 2007. View at: Publisher Site | Google Scholar
  60. S. George, B. C. Heng, K. J. Vinoth, A. Kishen, and T. Cao, “Comparison of the response of human embryonic stem cells and their differentiated progenies to oxidative stress,” Photomedicine and Laser Surgery, vol. 27, no. 4, pp. 669–674, 2009. View at: Publisher Site | Google Scholar
  61. R. Pamplona and D. Costantini, “Molecular and structural antioxidant defenses against oxidative stress in animals,” American Journal of Physiology Regulatory, Integrative and Comparative Physiology, vol. 301, no. 4, pp. R843–R863, 2011. View at: Publisher Site | Google Scholar
  62. C. H. Coyle and K. N. Kader, “Mechanisms of H2O2-induced oxidative stress in endothelial cells exposed to physiologic shear stress,” ASAIO Journal, vol. 53, no. 1, pp. 17–22, 2007. View at: Publisher Site | Google Scholar
  63. X. Ling, R. Nagai, N. Sakashita, M. Takeya, S. Horiuchi, and K. Takahashi, “Immunohistochemical distribution and quantitative biochemical detection of advanced glycation end products in fetal to adult rats and in rats with streptozotocin-induced diabetes,” Laboratory Investigation, vol. 81, no. 6, pp. 845–861, 2001. View at: Google Scholar
  64. L. G. Bucciarelli, T. Wendt, W. Qu et al., “RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice,” Circulation, vol. 106, no. 22, pp. 2827–2835, 2002. View at: Publisher Site | Google Scholar
  65. J. M. Nielsen, S. B. Kristiansen, R. Nørregaard et al., “Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice,” European Journal of Heart Failure, vol. 11, no. 7, pp. 638–647, 2009. View at: Publisher Site | Google Scholar
  66. N. Cao, Z. Liu, Z. Chen et al., “Ascorbic acid enhances the cardiac differentiation of induced pluripotent stem cells through promoting the proliferation of cardiac progenitor cells,” Cell Research, vol. 22, no. 1, pp. 219–236, 2012. View at: Publisher Site | Google Scholar
  67. H. M. Linge, J. Y. Lee, K. Ochani et al., “Age influences inflammatory responses, hemodynamics, and cardiac proteasome activation during acute lung injury,” Experimental Lung Research, vol. 41, no. 4, pp. 216–227, 2015. View at: Publisher Site | Google Scholar
  68. A. M. Pickering, A. L. Koop, C. Y. Teoh, G. Ermak, T. Grune, and K. J. Davies, “The immunoproteasome, the 20S proteasome and the PA28alphabeta proteasome regulator are oxidative-stress-adaptive proteolytic complexes,” The Biochemical Journal, vol. 432, no. 3, pp. 585–594, 2010. View at: Publisher Site | Google Scholar
  69. M. Hernebring, “26S and PA28-20S proteasome activity in cytosolic extracts from embryonic stem cells,” Methods in Molecular Biology, vol. 1341, pp. 359–367, 2016. View at: Publisher Site | Google Scholar

Copyright © 2017 Maria Barandalla et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

981 Views | 279 Downloads | 2 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.